OTCMKTS:DCHPF

Dechra Pharmaceuticals - DCHPF Stock Forecast, Price & News

$31.35

0.00 (0.00%)

(As of 03/31/2023 12:00 AM ET)

Add

Compare

Today's Range: $31.35
▼
$31.35
50-Day Range: $31.35
▼
$37.46
52-Week Range: $27.90
▼
$42.75

Volume: N/A
Average Volume: 843 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Dechra Pharmaceuticals (OTCMKTS:DCHPF) Stock

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Receive DCHPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCHPF Stock News Headlines

May 13, 2022 | finance.yahoo.com

Dechra Pharmaceuticals PLC (LON:DPH) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

March 16, 2022 | uk.finance.yahoo.com

FTSE 100 firms hit boardroom diversity targets but fail at executive level

April 1, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.

September 14, 2021 | finance.yahoo.com

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29

September 6, 2021 | finance.yahoo.com

Goldman Sachs picks London for private-equity IPO as FTSE climbs after U.S. jobs data

August 7, 2021 | finance.yahoo.com

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive DCHPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceuticals - Other
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:DCHPF
CUSIP: N/A
CIK: N/A
Web: dechra.com
Phone: 44.16.0681.4730
Fax: N/A
Employees: 1,699
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. Ian D. Page (Age 62)
CEO, MD & Exec. Director
Comp: $1.52M

Mr. Paul Nicholas Sandland MAAT (Age 44)
FCCA, CFO & Exec. Director
Comp: $952.39k

Dr. Anthony Gerard Griffin (Age 60)
MD of Dechra Veterinary Products for Europe & Exec. Director
Comp: $724.54k

Mr. Patrick Meeus
Group Scientific Officer

Ms. Katy Clough
Group HR Director

Mr. Mike Eldred (Age 53)
Pres of North America

Ms. Melanie Hall
Company Sec.

Key Competitors

View All Competitors

DCHPF Stock - Frequently Asked Questions

Should I buy or sell Dechra Pharmaceuticals stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DCHPF shares.
View DCHPF analyst ratings or view top-rated stocks.
How have DCHPF shares performed in 2023?: Dechra Pharmaceuticals' stock was trading at $32.2480 at the beginning of the year. Since then, DCHPF stock has decreased by 2.8% and is now trading at $31.3481.
View the best growth stocks for 2023 here.
What is Dechra Pharmaceuticals' stock symbol?: Dechra Pharmaceuticals trades on the OTCMKTS under the ticker symbol "DCHPF."

How do I buy shares of Dechra Pharmaceuticals?: Shares of DCHPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Dechra Pharmaceuticals' stock price today?: One share of DCHPF stock can currently be purchased for approximately $31.35.
How many employees does Dechra Pharmaceuticals have?: The company employs 1,699 workers across the globe.
How can I contact Dechra Pharmaceuticals?: Dechra Pharmaceuticals' mailing address is Cheshire Business Park, Northwich, Cheshire CW9. The official website for the company is dechra.com. The company can be reached via phone at 44.16.0681.4730.

This page (OTCMKTS:DCHPF) was last updated on 4/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial